爱维治、弥可保和东莨菪碱治疗糖尿病周围神经病变的疗效观察

Observation on therapeutic efficacy of Actovegin Methycobal Raceanisodamine on diabetic neuropathy

目的 :观察爱维治、弥可保和东莨菪碱 (654 -2)治疗糖尿病周围神经病变的疗效和安全性。方法 :在控制患者血糖的同时 ,分别给予弥可保500μg肌注 ,隔日1次,20天为1疗程,有效后继续肌注1疗程,然后改为口服;爱维治组给予爱维治1200mg加入生理盐水250ml静脉点滴,每日1次 (qd),14天为1疗程;654 -2组则给予血塞通0.3+654 -210mg加入生理盐水250ml静脉点滴,14天为1疗程。结果 :肢体疼痛的改善率 ,爱维治组分别高于弥可保组和654 -2组 ,肢体麻木的改善率 ,弥可保组高于爱维治组 ;感觉减退的改善率 ,弥可保组优于654 -2组(P<0.01)。结论 :对肢体麻木及感觉障碍的改善 ,弥可保优于爱维治 ,而爱维治则对肢体疼痛的疗效优于弥可保 ,优于血塞通 +654 -2。

Objective: To compare the therapeutic effect and safety of Actovegin Panax Notoginseng Saponins and 654-2 on diabetic neuropathy.Methods: The blood glucose was controlled, at the same time, the patients were also treated with Panax Notoginseng Saponins (500 μg.im.qod)for 20 days or Actovegin(1200 mg+N.S.250 ml iv.drip qd)for 2 weeks or 654-2(10 mg+N.S.250 ml iv. Drip)for 2 weeks. Results: The efficacy rate of melalgia abatement with Actovegin was higher than that of Panax Notoginseng Saponins and 654-2; The efficacy rate of numbness improvement with Panax Notoginseng Saponins was higher than that of Actovegin; The efficacy rate of hypoesthesia improvement with Panax Notoginseng Saponins was higher than that of 654-2(P<0.01).Conclusion: The improvement rate of numbness or hypoesthesia with Panax Notoginseng Saponins is better than that of Actovegin, but the efficacy of abatement of melalgia with Actovegin is better than that of Panax Notoginseng Saponins and 654-2.